Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA ...
The Series A Common Warrants and the Series B Common Warrants will have an exercise price of $0.35 per share. The Series A Common Warrants will be exercisable immediately and will expire five years ...
TUCSON, Ariz., April 22, 2026 (GLOBE NEWSWIRE)-- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the ...
TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE)-- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the ...
TUCSON, Ariz., April 15, 2026 (GLOBE NEWSWIRE)-- Picard Medical, Inc. (NYSE American: PMI) ("Picard Medical” or the "Company”), parent company of SynCardia Systems, LLC, maker of the world’s first ...
TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company ...
Scandinavian Real Heart today announced a new in vitro study backs its Realheart total artificial heart (TAH) system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results